Sanofi, a global biopharmaceutical company, and Regeneron Pharmaceuticals Inc, a leading biotechnology company, announced their intent to simplify antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) by restructuring into a royalty-based agreement. Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-US rights to Praluent. Regeneron is expected to gain sole US rights to Praluent. Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories. These changes are expected to increase efficiency and streamline operations for the products. The existing collaboration relating to Dupixent (dupilumab) will remain unchanged following the restructuring. Completion of the proposed agreement is expected to be finalised in the first quarter of 2020. Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.